US FDA approves Lilly's once-weekly insulin injection for type 2 diabetes

The US Food and Drug Administration has approved Eli Lilly's NYSE:LLY once-weekly basal insulin, Onswik, for adults with type 2 diabetes, the drugmaker said on Thursday, offering patients an alternative to daily long-acting insulin injections.Here are some details